Literature DB >> 8244102

Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance.

G Sciarretta1, A Furno, M Mazzoni, C Basile, P Malaguti.   

Abstract

Scintigraphy with autologous granulocytes labelled by technetium-99m hexamethyl, propylene amine oxime (99mTc-HMPAO) was performed in 103 Crohn's disease patients and 52 healthy controls. In 31 patients endoscopic and histologic activity was compared with scan activity index. In the 98 patients with a positive scan, the extent of Crohn's disease, assessed by scintigraphy, was compared with that evaluated by small bowel x ray or colonoscopy with biopsies. In 48 patients, Crohn's disease activity index, activity index, simple index, erythrocyte sedimentation rate, C-reactive protein were correlated with the scan results. In 16 patients the five parameters and scan were repeated after treatment with methyl-prednisolone (10 cases), enteral nutrition (3), and 5-acetylsalicylic acid (3). The results showed that 99mTc-HMPAO granulocyte scan had a 95% sensitivity and 100% specificity to detect active inflammation; it correctly showed an abscess or a fistula in all the 24 cases found. The correlation between histological inflammatory activity and scan activity index was highly significant (r = 0.85; p < 0.01), less significant (r = 0.65; p < 0.01) between endoscopy and scan activity index. The evaluation for the extent of Crohn's disease by scan was completely correct in the small bowel (100%) and 93% correct in the large bowel. No correlation was seen between the three clinical activity parameters and scanning; in more than 80% of the cases in remission on the basis of a clinical or laboratory index, scintigraphy remained positive. Medical treatment was effective on the clinical indices but not on the active inflammation in the ileum, whereas it led to a negative scan in 5/11 cases in the large intestine. Scintigraphy with 99mTc-HMPAO granulocyte plays an important part in Crohn's disease for the diagnosis of complications, for activity and assessment of the extent, and for the treatment results evaluation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244102      PMCID: PMC1374542          DOI: 10.1136/gut.34.10.1364

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

2.  Unsuspected extra-abdominal sites of infection: scintigraphic detection with indium-111-labeled leukocytes.

Authors:  J E Seabold; D G Wilson; L M Lieberman; C M Boyd
Journal:  Radiology       Date:  1984-04       Impact factor: 11.105

3.  Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; M B Pepys; H J Hodgson; V S Chadwick
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

4.  Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.

Authors:  C Andre; L Descos; P Landais; J Fermanian
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

5.  Location and activity of ulcerative and Crohn's colitis by indium 111 leukocyte scan. A prospective comparison study.

Authors:  D T Stein; G M Gray; P B Gregory; M Anderson; D A Goodwin; I R McDougall
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

6.  Ultrasonography and indium 111 white blood cell scanning for the detection of intraabdominal abscesses.

Authors:  B Carroll; P M Silverman; D A Goodwin; I R McDougall
Journal:  Radiology       Date:  1981-07       Impact factor: 11.105

7.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.

Authors:  H Malchow; K Ewe; J W Brandes; H Goebell; H Ehms; H Sommer; H Jesdinsky
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

8.  Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  An index of inflammatory activity in patients with Crohn's disease.

Authors:  P A van Hees; P H van Elteren; H J van Lier; J H van Tongeren
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

10.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

Authors:  W R Best; J M Becktel; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

View more
  15 in total

Review 1.  Role of scintigraphy in inflammatory bowel disease.

Authors:  Maria I Stathaki; Sophia I Koukouraki; Nikolaos S Karkavitsas; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

2.  Inflammatory bowel disease activity assessment using technetium-99m-HMPAO leukocytes.

Authors:  J W Arndt; M I Grootscholten; R A van Hogezand; G Griffioen; C B Lamers; E K Pauwels
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

3.  Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

Authors:  M H Giaffer
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

4.  Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods.

Authors:  J C Mansfield; M H Giaffer; W B Tindale; C D Holdsworth
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

5.  Quantification of inflammatory bowel disease activity using technetium-99m HMPAO labelled leucocyte single photon emission computerised tomography (SPECT).

Authors:  M J Weldon; A M Masoomi; A J Britten; J Gane; C J Finlayson; A E Joseph; J D Maxwell
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

Review 6.  Gastroenterology--II: Small and large bowel, pancreas and biliary system.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1994-09       Impact factor: 2.401

7.  Optimization of technetium-99m-HMPAO leukocyte scintigraphy in evaluation of active inflammatory bowel disease.

Authors:  M Sans; D Fuster; J Llach; F Lomeña; J M Bordas; R Herranz; J M Piqué; J Panés
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

8.  99mTc-HMPAO leucocyte scintigraphy fails to detect Crohn's disease in the proximal gastrointestinal tract.

Authors:  S M Davison; S Chapman; M S Murphy
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

9.  Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings.

Authors:  J J Kolkman; T H Falke; J C Roos; D H Van Dijk; I M Bannink; W Den Hollander; M A Cuesta; A S Peña; S G Meuwissen
Journal:  Dig Dis Sci       Date:  1996-04       Impact factor: 3.199

10.  PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine.

Authors:  Chandan Jyoti Das; Govind Makharia; Rakesh Kumar; Madhavi Chawla; Pooja Goswami; Raju Sharma; Arun Malhotra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.